Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#1804 Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT

Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ferolla P, Berruti A, Fazio N, Mazzanti P, Houchard A,

Keywords: Temozolomide, lanreotide,

#749 Natural History of Atypical Carcinoid of Lung After Surgery

Introduction: The natural history of atypical carcinoid (AC) is poorly known.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Marciello F, Mercier O, Ferolla P, Scoazec J, Planchard D,

Keywords: lung NET, atypical carcinoid, surgery, prognosis,

#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,

#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.

Conference:

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: Pasireotide, medullary thyroid cancer,

#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study

Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Faggiano A, Ferolla P, Dicitore A, Castiglioni S, Borghi M,

Keywords: medullary thyroid cancer, neuroendocrine tumor, RAD001, Everolimus, octreotide, antitumor activity,